Cardiovascular adverse events and prognosis in patients with hematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.

This study revealed that 16-38% of patients with hematologic malignancies and breast cancer developed CTR-CVT during follow-up, in which patients with high/very high-risk were well predicted by the HFA-ICOS risk assessment tool. Monitoring and managing CV risk factors are essential for safe cancer therapy.